Back to search results

Allogeneic HB-adMSCs vs Placebo for the Treatment of Acute Kidney Injury

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Acute Kidney Injury

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Alabama at Birmingham, Birmingham, Alabama, United States

    Contact: Study coordinator (Sabrina Goddard, MD)
    Contact: Principal Investigator (Sabrina Goddard, MD)
    John B Holcomb, MD (Sub-investigator)

  • University of California, San Francisco, San Francisco, California, United States

    Contact: Study coordinator (Joseph Cuschieri, MD)
    Contact: Principal Investigator (Joseph Cuschieri, MD)
    Contact: Principal Investigator (Shibani Pati, MD, PhD)
    Kathleen Liu, MD, PhD (Sub-investigator)
    Lucy Kornblith, MD (Sub-investigator)

  • University of Texas Health Science Center at Houston (UTHealth Houston), Houston, Texas, United States

    Contact: Study coordinator (Charles S Cox, Jr., Dr.) · Charles.S.Cox@uth.tmc.edu · 713-500-7307
    Contact: Principal Investigator (Charles S Cox, Jr., Dr.)
    Erin E Fox, PhD (Sub-investigator)
    John Harvin, MD, MS (Sub-investigator)
    Laura Moore, MD (Sub-investigator)
    Claudia Pedroza, PhD (Sub-investigator)
Study leads

  • Charles S Cox, Jr., MD

    Principal Investigator

    The University of Texas Health Science Center, Houston

View source on ClinicalTrials.gov(opens in a new tab)